Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma
Yahoo Finance
Yahoo Finance
Sign in
?
Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma
Immix Biopharma, Inc.
Mon, Oct 2, 2023, 5:06 AM PDT11 min read
IMMX+20.91%
Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma
Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma
95% overall response rate observed in relapsed/refractory multiple myeloma patients not previously treated with BCMA-targeted therapy. Median progression free survival (mPFS) was 12.9 months as of the July 17, 2023 data cut-off
90% overall response rate observed in relapsed/refractory multiple myeloma at the therapeutic dose including patients with, and without prior BCMA-targeted therapy
Class-Leading Response Rate in BCMA-exposed patients (frequently excluded from BCMA CAR-T clinical trials) has the potential to meet an important market need
ImmixBio plans to submit a BLA for FDA approval in multiple myeloma once 100 patients are treated with NXC-201
The expected primary endpoints for NXC-201 in relapsed/refractory multiple myeloma are overall response rate and duration of response